Related Experiment Video
Updated: Nov 9, 2025

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
Published on: March 23, 2022
[Clinical features and gene mutations of 6 patients with carnitine palmitoyltransferase 1A deficiency]
1Department of Pediatric Endocrinology and Genetic Metabolism, Shanghai Xinhua Children's Hospital, Shanghai Institute for Pediatric Research, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China.
Insights
Carnitine palmitoyltransferase 1A deficiency (CPT1A) diagnosis is improved by analyzing patient data and gene sequencing. Tandem mass spectrometry aids in early CPT1A screening and diagnosis.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Background:
- Carnitine palmitoyltransferase 1A (CPT1A) deficiency is a rare metabolic disorder.
- Understanding CPT1A deficiency is crucial for early diagnosis and management.
Purpose of the Study:
- To analyze clinical, biochemical, and genetic data of CPT1A deficiency patients.
- To enhance the understanding of CPT1A deficiency.
- To identify novel mutations in the CPT1A gene.
Main Methods:
- Retrospective analysis of clinical and biochemical data from six CPT1A deficiency patients.
- Gene sequencing of the CPT1A gene.
- Tandem mass spectrometry for carnitine and acyl carnitine analysis.
Main Results:
- Six patients (5 male, 1 female; aged 1-8 years) were included.
- Two patients detected via neonatal screening were asymptomatic; four presented with seizures.
- Biochemical analysis revealed increased serum free carnitine (C0) and decreased C16/C18, with elevated C0/(C16+C18).
- All patients had compound heterozygous CPT1A mutations, including two known and ten novel mutations (6 missense, 1 nonsense, 1 deletion, 2 splicing).
Conclusions:
- Tandem mass spectrometry is valuable for early screening and diagnosis of CPT1A deficiency.
- Identification of novel CPT1A mutations expands the known mutation spectrum.
- Comprehensive analysis improves understanding of CPT1A deficiency's clinical and genetic landscape.
Abstract:
The clinical and biochemical data and gene sequencing results of patients with carnitine palmitoyltransferase 1A deficiency were analyzed, in order to improve the understanding of the disease. Six patients (5 males and 1 female, aged from 1 to 8 years old) with carnitine palmitoyltransferase 1A deficiency from Department of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital between 2008 and 2019 were included. Two cases were detected by neonatal screening and had no clinical symptoms. The remaining 4 cases all showed seizures induced by fever, vomiting or diarrhea. All the 6 patients showed increased serum free carnitine (C0), decreased hexadecanoylcarnitine (C16) and octadecanoylcarnitine (C18), and increased C0/(C16+C18). Meanwhile, compound heterozygous mutations of CPT1A gene were detected in all 6 patients, of which 2 were reported mutations (c.281+1G>A and c.968-8C>T), and 10 were new mutations. The new mutations included 6 missense mutations, 1 nonsense mutation, 1 deletion mutation and 2 splicing mutations. Detection of free carnitine and acyl carnitine by tandem mass spectrometry is helpful for early screening and diagnosis of carnitine palmitoyltransferase 1A deficiency.
Related Concept Videos
Inborn Errors of Metabolism
Lysosomal Hydrolases
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Smooth Endoplasmic Reticulum
The ER provides optimal conditions for synthesizing steroid hormones and lipids, such as phospholipids and triglycerides. Traditionally, lipid metabolism was considered to be a smooth ER function. However, there is no direct evidence to prove that rough ER is completely excluded from lipid...
Cardiomyopathy IV: Restrictive Cardiomyopathy

